65,437 trials
Hiv · HIV/AIDS · Medication Adherence
Primary: Intervention Feasibility: Average Proportion of Days of Any App Use — 0.64; 0.40; 0.27; 0.64 proportion of days
Breast Cancer Lymphedema
Primary: Compliance Measured as the Average Number of Treatments Per Week — 5.3; 5.2 treatments/week
Out-Of-Hospital Cardiac Arrest
Primary: Number of Participants Who Survived to Hospital Admission — 218; 205; 212 Participants — p=0.82
HIV Infections
Primary: Percentage of Infants Experiencing at Least One Grade 3 or Higher Adverse Event (AE) — 40.0; 46.7 Percentage of participants — p=0.79
Prostate Cancer
Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants
Stage II Prostate Adenocarcinoma · Stage III Prostate Adenocarcinoma · Stage IV Prostate Adenocarcinoma
Primary: Sensitivity, Specificity, Positive, and Negative Predictive Value of 68Ga-RM2 PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical…
Tuberculosis, Multidrug-Resistant
Primary: Time to Sputum Culture Conversion — 5.9; 6.3; 6.1; 6.1 weeks
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
PTSD
Primary: Clinician Administered PTSD Scale, 5 (CAPS-5) — 31.55; 25.12; 29.59; 25.41 score on a scale
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045
Chronic Migraine
Primary: Number of Participants With Adverse Events — 1 Participants
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
Neonatal Abstinence Syndrome
Primary: Length of Hospital Stay — 17.9; 16.1 days
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Change in Tumor Size — 1; 3; 11 Participants
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3